Quarterly ResultAug 10, 2026, 07:23 AM
Silence Therapeutics Q2 Net Loss Reduced to $12.3M; Clinical Progress
AI Summary
Silence Therapeutics reported its second quarter 2026 financial and business results, showing a significant reduction in net loss to $12.3 million, down from $27.4 million in the prior year. R&D expenses also decreased to $9.1 million. The company announced the completion of patient dosing in the Phase 2 SANRECO trial for divesiran and presented positive Phase 1 results for SLN312. Additionally, two preclinical programs, SLN365 and SLN098, are on track for IND filings in 2027.
Key Highlights
- Q2 2026 net loss significantly reduced to $12.3 million from $27.4 million year-over-year.
- Research and development expenses decreased to $9.1 million in Q2 2026 from $17.6 million in Q2 2025.
- Cash and cash equivalents were $72.1 million as of June 30, 2026.
- Completed patient dosing in the Phase 2 SANRECO trial for divesiran in June 2026.
- Presented positive Phase 1 results for SLN312 (AZD1705) at the EAS Congress in May.
- Preclinical programs SLN365 and SLN098 are positioned for IND filings in 2027.
Price Impact
More from SLN